Monotherapy in adults and elderly persons

Area of Science:

• Neurology
• Pharmacology

Background:

• Epilepsy management often involves antiepileptic drugs (AEDs).
• Monotherapy (single drug) versus polytherapy (multiple drugs) presents distinct clinical considerations.
• Elderly patients with epilepsy have unique pharmacokinetic and pharmacodynamic challenges.

Purpose of the Study:

• To highlight the advantages of monotherapy in epilepsy treatment.
• To discuss the suitability of monotherapy for elderly patients with epilepsy.
• To review current recommendations for AED selection.

Main Methods:

• Review of potential benefits of monotherapy including adverse events, drug interactions, cost, and compliance.
• Consideration of pharmacokinetic interactions and conversion from polytherapy to monotherapy.
• Analysis of treatment guidelines for AED selection in adults and elderly patients.

Main Results:

• Monotherapy offers benefits such as fewer adverse events, better tolerability, avoidance of drug-drug interactions, reduced costs, and improved compliance.
• Pharmacokinetic interactions are minimized with monotherapy.
• Elderly patients present challenges including altered pharmacokinetics, increased sensitivity to CNS side effects, and potential drug interactions with comorbidities.

Conclusions:

• Initial epilepsy treatment should be monotherapy.
• Monotherapy is particularly attractive for elderly patients due to age-related factors and polypharmacy.
• Evidence does not conclusively support polytherapy over monotherapy for the majority of patients.